Chronic rhinosinusitis in cystic fibrosis patients is relieved by elexacaftor-tezacaftor-ivacaftor therapy: JAMA.

Published Date: 22 Sep 2023

USA: Elexacaftor, Tezacaftor, and Ivacaftor (ETI; Trikafta) therapy is linked to better clinical outcomes and chronic sinus disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot